ClinicalTrials.Veeva

Menu

Hyoscine Butylbromide Effect on Duration of Labor

S

Saint Thomas Hospital (HST)

Status

Completed

Conditions

Labor

Treatments

Drug: Saline Solution
Drug: Hyoscine Butylbromide 20Mg/1mL Injection

Study type

Interventional

Funder types

Other

Identifiers

NCT03441217
MHST2014-05

Details and patient eligibility

About

To evaluate the duration of labour (active phase of labour) in nulliparous women with gestations between 37 and 41 6/7 weeks when 20 mg of Hyoscine butylbromide was applied intravenously and compared with similar patients that received a placebo.

Enrollment

218 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Low risk gestation between 37 and 41 6/7 weeks.
  • Cephalic (vertex) presentation.
  • Spontaneous labor in active phase (4 cms)

Exclusion criteria

  • Premature rupture of membranes upon arrival at the Labor and Delivery Unit > 4 hours.
  • Multiple order pregnancy.
  • Stillbirth.
  • Any fetal condition that could interfere in the mode of delivery (macrosomia, fetal growth restriction, oligohydramnios).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

218 participants in 2 patient groups, including a placebo group

Hyoscine Butylbromide 20Mg/1mL Injection
Experimental group
Description:
Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
Treatment:
Drug: Hyoscine Butylbromide 20Mg/1mL Injection
Saline solution
Placebo Comparator group
Description:
Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
Treatment:
Drug: Saline Solution

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems